(NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management
I love their fast shipping, great service, and good guarantees
doi: 10.3390/ijerph191811635
July 18, 2025: Chinese Obesity Drug Outperforms Zepbound in Helping Patients Lose Weight, Trials Show A new obesity drug, HRS9531, made by the Chinese company Hengrui Pharma may help patients lose more weight than when on Zepbound
JAMA Internal Medicine (2016): In over 1.5 million patients, incretin-based drugs, including GLP-1s, had an adjusted hazard ratio of 1.04 (95% CI, 0.811.35) for acute pancreatitis
Medical know-how: Once youve had a PICC line and have self-administered intravenous antibiotics, other medical procedures seem like a snap